The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
NEUROPACE, INC. COMMON STOCK 641288105 46,149 5,621,111 SH   SOLE   5,621,111 0 0
SIGHT SCIENCES, INC. COMMON STOCK 82657M105 55,213 4,776,232 SH   SOLE   4,776,232 0 0
IMMUNIC, INC. COMMON STOCK 4525EP101 788 69,704 SH   SOLE   69,704 0 0
AILERON THERAPEUTICS, INC. COMMON STOCK 00887A105 331 646,817 SH   SOLE   646,817 0 0